Michael Princiotta's Contact Details

Michael Princiotta's Company Details

EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. \\Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. \\EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient's unique tumor and normal genome sequence (the mutanome).\\EpiVax Oncology's ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. \\EpiVax Oncology's ambition is to become a premier cancer precision medicine company, leveraging EpiVax's world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.